Salarius Pharmaceuticals, Inc. – NASDAQ:SLRX
Salarius Pharmaceuticals stock price today
$5.8
+4.13
+247.31%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
Salarius Pharmaceuticals stock price monthly change
-15.66%
month
Salarius Pharmaceuticals stock price quarterly change
-15.66%
quarter
Salarius Pharmaceuticals stock price yearly change
+197.42%
year
Salarius Pharmaceuticals key metrics
Market Cap | 2.14M |
Enterprise value | N/A |
P/E | -0.12 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | 0.30 |
PEG ratio | N/A |
EPS | -2.71 |
Revenue | N/A |
EBITDA | -9.23M |
Income | -8.91M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeSalarius Pharmaceuticals stock price history
Salarius Pharmaceuticals stock forecast
Salarius Pharmaceuticals financial statements
| Jun 2023 | 0 | -3.87M | |
|---|---|---|---|
| Sep 2023 | 0 | -2.44M | |
| Dec 2023 | 0 | -881.79K | |
| Mar 2024 | 0 | -1.71M |
| Mar 2024 | 0 | -1.71M | |
|---|---|---|---|
| Sep 2025 | 0 | -197.65M | |
| Dec 2025 | 0 | -3.75M | |
| Dec 2025 | 0 | -197.65M |
Analysts Price target
Financials & Ratios estimates
0%
Yield TTM
| Payout ratio | 0% |
|---|
| 2019 | 0.14% |
|---|---|
| 2020 | |
| 2021 | |
| 2022 | |
| 2023 |
| Jun 2023 | 12055298 | 3.64M | 30.21% |
|---|---|---|---|
| Sep 2023 | 8404228 | 2.32M | 27.61% |
| Dec 2023 | 6586523 | 1.29M | 19.73% |
| Mar 2024 | 4883659 | 1.23M | 25.27% |
| Jun 2023 | -4.41M | 0 | 6.68M |
|---|---|---|---|
| Sep 2023 | -3.74M | 0 | -211.82K |
| Dec 2023 | -1.51M | 0 | -169.44K |
| Mar 2024 | -1.35M | 0 | -172.75K |
Salarius Pharmaceuticals alternative data
| Aug 2023 | 12 |
|---|---|
| Sep 2023 | 12 |
| Oct 2023 | 12 |
| Nov 2023 | 12 |
| Dec 2023 | 12 |
| Jan 2024 | 12 |
| Feb 2024 | 12 |
| Mar 2024 | 2 |
| Apr 2024 | 2 |
| May 2024 | 2 |
| Jun 2024 | 2 |
| Jul 2024 | 2 |
Salarius Pharmaceuticals other data
2.59%
-0.64%
of SLRX is owned by hedge funds
55.06K
-17.62K
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Aug 2021 | 11000 | 0 |
| Mar 2022 | 215734 | 0 |
| May 2022 | 71900 | 0 |
| Jun 2022 | 119753 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | BURLESON TESS director | Common Stock | 27,700 | $0.18 | $4,986 | ||
Purchase | LIEBER JONATHAN I director | Common Stock | 37,500 | $0.19 | $7,013 | ||
Purchase | MCVICAR WILLIAM K. director | Common Stock | 26,553 | $0.19 | $4,992 | ||
Purchase | HANISH ARNOLD C director | Common Stock | 28,000 | $0.18 | $5,152 | ||
Purchase | ROSENBLUM MARK J officer: Exec VP .. | Common Stock | 28,000 | $0.18 | $5,040 | ||
Purchase | ARTHUR DAVID J. director, officer: Chief Execut.. | Common Stock | 10,800 | $0.18 | $1,987 | ||
Purchase | ARTHUR DAVID J. director, officer: Chief Execut.. | Common Stock | 10,392 | $0.18 | $1,871 | ||
Purchase | ARTHUR DAVID J. director, officer: Chief Execut.. | Common Stock | 708 | $0.18 | $127 | ||
Purchase | ARTHUR DAVID J. director, officer: Chief Execut.. | Common Stock | 18,600 | $0.18 | $3,385 | ||
Purchase | ARTHUR DAVID J. director, officer: Chief Execut.. | Common Stock | 3,400 | $0.18 | $612 |
| Quarter | Transcript |
|---|---|
| Q2 2022 8 Aug 2022 | Q2 2022 Earnings Call Transcript |
| Q1 2022 12 May 2022 | Q1 2022 Earnings Call Transcript |
| Q4 2021 10 Mar 2022 | Q4 2021 Earnings Call Transcript |
| Q3 2021 7 Nov 2021 | Q3 2021 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Mr. David J. Arthur M.B.A. (1963) Chief Executive Officer, Pres & Director | $530,900 |
| Mr. Mark J. Rosenblum (1953) Executive Vice President of Fin. & Chief Financial Officer | $394,210 |
-
What's the price of Salarius Pharmaceuticals stock today?
One share of Salarius Pharmaceuticals stock can currently be purchased for approximately $5.8.
-
When is Salarius Pharmaceuticals's next earnings date?
Unfortunately, Salarius Pharmaceuticals's (SLRX) next earnings date is currently unknown.
-
Does Salarius Pharmaceuticals pay dividends?
No, Salarius Pharmaceuticals does not pay dividends.
-
How much money does Salarius Pharmaceuticals make?
Salarius Pharmaceuticals has a market capitalization of 2.14M.
-
What is Salarius Pharmaceuticals's stock symbol?
Salarius Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "SLRX".
-
What is Salarius Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Salarius Pharmaceuticals?
Shares of Salarius Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Salarius Pharmaceuticals's key executives?
Salarius Pharmaceuticals's management team includes the following people:
- Mr. David J. Arthur M.B.A. Chief Executive Officer, Pres & Director(age: 62, pay: $530,900)
- Mr. Mark J. Rosenblum Executive Vice President of Fin. & Chief Financial Officer(age: 72, pay: $394,210)
-
How many employees does Salarius Pharmaceuticals have?
As Jul 2024, Salarius Pharmaceuticals employs 2 workers.
-
When Salarius Pharmaceuticals went public?
Salarius Pharmaceuticals, Inc. is publicly traded company for more then 10 years since IPO on 29 Jan 2015.
-
What is Salarius Pharmaceuticals's official website?
The official website for Salarius Pharmaceuticals is salariuspharma.com.
-
Where are Salarius Pharmaceuticals's headquarters?
Salarius Pharmaceuticals is headquartered at 2450 Holcombe Boulevard, Houston, TX.
-
How can i contact Salarius Pharmaceuticals?
Salarius Pharmaceuticals's mailing address is 2450 Holcombe Boulevard, Houston, TX and company can be reached via phone at 832 834 6992.
Salarius Pharmaceuticals company profile:
Salarius Pharmaceuticals, Inc.
salariuspharma.comExchange:
NASDAQ
Full time employees:
2
Industry:
Biotechnology
Sector:
Healthcare
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.
2450 Holcombe Boulevard
Houston, TX 77021
Houston, TX 77021
CIK: 0001615219
ISIN: US79400X3052
CUSIP: 79400X107
